CYBERDYNE





Consolidated Financial Results Briefing for the six months ended September 30, 2026

CYBERDYNE, INC. (Ticker Code: 7779)
Nov 12, 2026

Consolidated financial statements

Consolidated Six months Results Summary (IFRS)

Revenue increased and operating loss narrowed year on year, mainly driven by higher sales from product rentals and other services in Japan and APAC and treatment services and other services in the U.S. and EMEA.
Profit before tax and net income decreased year on year, mainly due to a decrease in gains on the valuation of investment securities.

(Millions of yen)	2025/1H	2026/1H	+/-	+/- %
Revenue	1,963	2,008	+ 45	+2.3%
Operating profit (loss)	△ 174	△ 124	+ 50	-
Profit before tax	297	170	△ 127	△42.9%
Profit attributable to owners of parent	70	54	△ 16	△22.5%

Revenue

2,008 Million
YoY +45 Million

- Domestic & APAC product rentals, etc.: +26 million yen (business -2 million yen, forex +28 million yen)
- EMEA product rentals: -82 million yen (business -99 million yen, forex +18 million yen)
- Treatment services: +130 million yen (business +50 million yen, forex +79 million yen)
- Others(domestic): -33 million yen

Operating profit (loss)

-124 Million
YoY +50 Million

- Domestic & APAC product rentals, etc.: +45 million yen (business +27 million yen, forex +18 million yen)
- EMEA product rentals: -80 million yen (business -86 million yen, forex +7 million yen)
- Treatment services: +16 million yen (business +19 million yen, forex -3 million yen)
- Others(domestic): -13 million yen
- R&D and head office expenses, etc.: +76 million yen (decrease in expenses)

Profit before tax

170 Million
YoY -127 Million

- Operating profit variance: +50 million yen
- Financial income, mainly consisting of gain on valuation of investment securities: -217 million yen
  (FY2026 1H: +410 million yen vs. FY2025 1H: +627 million yen)
- Finance cost and others: +40 million yen (FY2026 1H: -116 million yen vs. FY2025 1H: -156 million yen)

※ Exchange Rate USD/JPY: Mar 159.88 → Sep 157.35 (YoY: Mar 149.52 → Sep 148.88)
EUR/JPY: Mar 183.41 → Sep 178.34 (YoY: Mar 162.08 → Sep 174.47)

Consolidated results: Revenue / Operating profit (Margin) (Six-month period)

Revenue from product rentals and other services increased in Japan, APAC and the U.S., while it decreased in EMEA, mainly in Ukraine and other countries, resulting in an overall decrease year on year.

Revenue from treatment services and other services increased in the U.S. and EMEA, resulting in an overall increase year on year.

(Millions of yen)		2025/1H	2026/1H	+/-	+/- %
Product rental	Revenue Operating Profit (Margin %)	1,030 495 (48%)	978 465 (48%)	△ 52 △ 31 (△1%)	△5% △6%
Treatment service	Revenue Operating Profit (Margin %)	822 △ 46 (△6%)	952 △ 29 (△3%)	+ 130 + 16 (2%)	+16% -
Others	Revenue Operating Profit (Margin %)	112 6 (5%)	79 △ 7 (△9%)	△ 33 △ 13 (△14%)	△30% -
R&D expenses& Head office expenses	Adjusted amount	△ 630	△ 553	+ 77	-
Consolidated total(IFRS)	Revenue Operating Profit (Margin %)	1,963 △ 174 (△9%)	2,008 △ 124 (△6%)	+ 45 + 50 (3%)	+2% -

- Amount of operating profit or loss, which is revenue minus operating expenses, for each business
- Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Product rental：Revenue from rental of the Group's products（includes revenue from sales）
- Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- Others：Revenue from the Group's other business (e.g. subsidiary in Sleeping App)

Revenue by geographical regions and type of transaction (Six-month period)

(Unit : Millions of yen) Top : FY2026/1H (Bottom : FY2025/1H)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	489 (488)	163 (245)	302 (277)	24 (20)	978 (1,030)	△ 52 (△ 5%)
Treatment Service	59 (62)	45 (33)	- (-)	848 (726)	952 (822)	+130 (+ 16%)
Others	79 (112)	- (-)	- (-)	- (-)	79 (112)	△ 33 (△ 30%)
Total	627 (662)	208 (278)	302 (277)	872 (746)	2,008 (1,963)	+45 (+ 2%)
YoY	△ 35 (△ 5%)	△ 71 (△ 25%)	+24 (+ 9%)	+126 (+ 17%)		
	Domestic	Foreign				
Revenue to sales ratio	31%	69%			100%	

EMEA :Europe, the Middle East and Africa
APAC : Asia-Pacific *Excluding Japan
AMER : North, Central and South America

Rental revenue by each products (Six-month period)


(Unit : Millions of yen) Top : FY2026/1H (Bottom : FY2025/1H)	Type of product	In Japan	Outside Japan	Total
Cybernics Treatment Functional improvement and regeneration	Medical HAL Lower Limb Type	231 (210)	296 (385)	527 (595)
	Non-medical HAL Lower Limb Type	65 (76)	- (-)	65 (76)
	HAL Single Joint Type	46 (48)	75 (75)	120 (123)
Well-being and care	HAL Lumbar Type	39 (40)	69 (58)	108 (98)
Labor Support	HAL Lumbar Type	16 (18)	- (-)	16 (18)
	Mobile robot (CL02 etc.)	40 (51)	- (-)	40 (51)
Other（Acoustic X、Other products)		54 (45)	48 (24)	102 (69)
Total		489 (488)	489 (542)	978 (1,030)

Business Policy and Initiatives for Business Growth

Realization of “Techno-peer Support Society”

A future society where people and technology coexists, cooperates and mutually support each other

For wide variety of people faced with health, physical function, cognitive and psychological problems
A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernics Technology: Innovative core technology of Cybernics Industry

Cybernics: Fuses and combines humans, AI-Robots and Information Systems



***Cybernics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernics as pioneering cutting-edge innovative science and technology areas

→ Toward the creation of the "Cybnics Industry" following the robotics and IT industries


Business development centered on Cybernics (HCPS-integrated Cybernics with Physical AI) within a fusion space of humans and cyber/physical space

CYBERDYNE

Improving the well-being of seniors and people with disability




Improving the well-being through supporting and supervising solutions




Towards the 5th Industrial Revolutions!
"Human"+"Cyber/Physical Space"

HCPS-integrated Cybernics with Physical AI Cybernics Industry


that will follow Robot and IT Industry



Prevention, early detection and medical/healthcare



Work support and improving efficiency through AI automation



Future of medical healthcare and healthy life
Prevention/early detection, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life

Pre-Hospital
Early medical・life period Prevent/early detection

Hospital
Diagnose, treat, inpatient/outpatient

Post-Hospital
Late medical・life period : rehab/long-term care

early medical・life period


Acute

Recovery

Late medical・life period

Household・work place・life space


Household・work place・life space



Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

Wearable Cyborg: Launch of rental sales for the next-generation Medical HAL Lower Limb Type (ML08)

Launch of rental sales for the new model of the Medical HAL Lower Limb Type (from May 2026)



Key Features of the New Model

✓Improved operational efficiency through size integration

Available in two types with different waist widths.
A single unit supports users from 150cm to 190cm in height, significantly simplifying operations compared to the conventional multi-size lineup.

✓More powerful and stable assistance

With a structure designed to firmly support the wearer and improved efficiency in transmitting assistive force, the system **enhances walking stability and provides greater confidence during use**.

✓Enabling more natural and comfortable walking

Enhanced algorithms with AI-based posture assessment enable more natural walking, making treadmill walking and faster-paced walking easier to perform. In addition, the design minimizes the sensation of device weight, reducing fatigue and improving comfort during extended use.

✓High durability and ease of use

Frame rigidity and durability have been improved, reducing wear and risk of failure. The design also minimizes loosening and misalignment during use, improving day-to-day operability.

【Prevention/Early detection, Diagnosis check】Small vital sensor “Cyvis”

Early detection, early treatment, and prognostic management of cardiovascular diseases — contributing to the prevention of stroke and dementia.

Through continuous daily monitoring, atrial fibrillation — which can lead to thrombus formation causing cerebral infarction and vascular dementia — can be detected and addressed at an early stage.







Key Features of Cyvis M100

✓ **Long-term continuous monitoring**
- Enables approximately 10 days of ECG monitoring on a single charge

✓ **Simultaneous measurement of various types of data**
- Acceleration (body movement) and angle
- Atmospheric pressure
- Body surface temperature, in-clothing temperature, and humidity*

*To be released in phases

✓ **Easy data review via app**
- Measurement data can be easily checked using a smartphone app
- Activity records can also be easily entered through the app

✓ **No manual data extraction required / Remote access available**
- Measurement data is automatically stored in a secure cloud via smartphone or tablet
- Data can also be viewed remotely through a PC browser

【Prevention/Early detection, Diagnosis check】Small vital sensor “Cyvis”

Cyvis M100 Holter ECG Testing Support Service for Medical Institutions





Japanese reimbursement for Holter ECG testing
8 hours or longer: 1,730 points/test
7 days or longer: 2,050 points/test*
1 point = ¥10
*A 320-point long-duration ECG add-on was introduced in the FY2026 medical fee revision


Introductory campaign*
Eligible: medical institutions in Japan
Initial fee: ¥0
Monthly base fee: ¥18,000
Usage fee: ¥6,600 per test


Prices exclude consumption tax
*Terms and conditions apply

【Prevention/Early detection, Diagnosis check】Small vital sensor “Cyvis”

**By aggregating data in the cloud and utilizing AI analysis,
medical and non-medical fields can be interconnected and integrated.**

Hospital





Deployment as a medical device covered by insurance reimbursement
(Holter ECG monitoring)

Emergency



Workplaces



Deployment as a corporate employee health management service



C-Cloud


Data sharing and centralized management

ECG data

Vital signs information

Analysis results and alerts

Home





Deployment as a personal healthcare
(remote monitoring) service



Remote family members

Care facilities






Deployment as a resident monitoring service for care facilities and other organizations

Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)



Adopted as the cover of BioPhotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!

Example of application

- **Routine examination and diagnosis of diabetic foot lesions**
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device

Examples of business development for the “HCPS-Integrated Cybernics with Physical AI Platform”:As a medical technology solutions business that combines multiple Cybernics technologies, we plan to develop and expand next-generation treatment and care systems.

Wearable Cyborg “HAL”

Wearable Cyborg “HAL” including AI

driven by BioElectrical Signals derived from Brain






Vital Sensor “Cyvis”

Vital Sensor “Cyvis”


Bioelectrical Signal (ECG, EEG etc), Movement, BodyTemperature, SpO2 and Breath condition(option), etc



PhotoAcoustic Imaging System “AcousticX”

PhotoAcoustic Imaging System “AcousticX”

No Xray, No Contrast-media, Non-invasive, Real-time, High-resolution 3D imaging of Peripheral Blood Vessels



Clinical Research model



Medical device

An integrated approach encompassing prevention, early detection, treatment, and daily health management (monitoring and improvement).

Data acquired from each device is aggregated, AI-analyzed, and AI-processed through the C-Cloud platform, enabling the development of comprehensive medical and healthcare service businesses.

Examples of the HCPS-Integrated Cybernics with Physical AI Platform

Business development centered on Cybernics (HCPS-integrated Cybernics with Physical AI) within a fusion space of humans and cyber/physical space

Expanding our business operations and promote business development and R&D in the second stage

1st stage (Conventional products)

Promoting R&D, clinical research, clinical trials, insurance coverage, and global expansion centered on medical HAL for Cybernics treatment.
Deployment of AI-powered cleaning robots and AI image-processing 3D photoacoustic imaging systems.



2nd stage (Next-generation and new products)

Next-generation HAL



Slim HAL Lumbar Type






Next-generation Medical HAL Lower Limb Type

Cyvis + AI automated assessment



Compact vital sensor Cyvis M100

Cell culture Physical AI



Cell culture Physical AI

Autonomous and remote-operation Physical AI



Simplified hybrid autonomous/remote-operation Physical AI (to be progressively implemented in cleaning, transport, and AI mobility applications)



Advanced hybrid autonomous/remote-operation Physical AI (multi-purpose applications including biotechnology, maintenance, and operational tasks)

Photoacoustic + AI image processing: Medical AcousticX



Peripheral vascular and circulatory photoacoustic imaging AcousticX (medical device)

HCPS platform: C-Cloud (data aggregation and AI processing)

2026 2027

Clinical Development

Medical device approval for Medical HAL Lower Limb Type

Obtained medical device approvals and certifications in Europe and the US for cerebral palsy and spinal cord disorders

As of September 30, 2026

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	• HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
USA		Approved	Approved	Approved	• Cerebral palsy *Over 12 yrs old • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
EMEA	Europe	Approved	Approved	Approved	• Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	Approved	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Clinical Development Pipeline

As of September 30, 2026

	Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/ examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Lower Limb	Neuromuscular Disease (8 types of disease such as ALS and muscular dystrophy)								Coverage under public health insurance
									Approved as medical device
									Approved as medical device
	Spinal related disease (2 diseases virus and hereditary)								Coverage under public health insurance
									Approved as medical device
									Approved as medical device
	Spinal Cord Injury								Communicating with regulators
								Public workers Compensation insurance (Germany)	Trial towards public health insurance started (Germany)
									Approved as medical device
	Stroke								Preparing for additional clinical trial
									Approved as medical device
									Approved as medical device
Lumbar	Parkinsons Disease								Preparing for clinical trial


<Spinal cord injury (Germany)>
Trial toward public health insurance coverage started
(first patient treated in August 2026)

Stroke (Japan)
preparing a clinical trial using the new model of the Medical HAL Lower Limb Type Double-leg model based on the latest patient profiles and clinical needs

Preparing clinical trials for Lumbar type based on favorable results from pilot trials

Wearable cyborg HAL

HAL identified as the only device that induces neuroplasticity and provides comprehensive therapeutic effects — published in an international medical journal (comparison with passively controlled exoskeleton-type devices)



Review Article

AO SPINE

Actively Controlled Exoskeletons Show Improved Function and Neuroplasticity Compared to Passive Control: A Systematic Review

Global Spine Journal
2025, Vol. 15(8) 3933–3952
© The Author(s) 2025
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/21925682251343529
journals.sagepub.com/home/gsj
Sage

Ka Ioi Argu
James Gedd
and Darren

A systematic review analyzed 27 clinical studies selected from 555 publications released over a 12-year period, providing one of the highest levels of scientific evidence.

Abstract

Study Design: Systematic Review.

Objectives: To determine whether actively controlled exoskeletons or passively controlled exoskeletons are better at rehabilitating patients with SCIs.

Methods: A literature search between January 2011 to June 2023 on Pubmed Central, Pubmed, Web of Science and Embase was carried out. Exoskeletons were classified as actively controlled if they detect bioelectrical signals (HAL). All other exoskeletons were classified as passively controlled (ReWalk, Ekso, H-MEX, Atlante, Indego, Rex Bionics, SuitX Phoenix, Lokomat and HANK). Functional outcomes used were 6 minute walk test (6MWT) distance and 10 metre walk test (10MWT) speed. Further subgroup analysis was carried out for acute and chronic SCI patients. All outcomes were examined without the aid of the exoskeleton device. Secondary outcomes including continence, pain and quality of life were also examined.

Results: 555 articles were identified in the initial search and 27 were included in the review resulting in a total of 591 patients and 10 different exoskeleton models. HAL was the only exoskeleton to show improvements in both mobility and all secondary health outcomes. HANK and Ekso also showed improvements in mobility. Rewalk showed improvements in all secondary health outcomes with Ekso only showing improvements in QoL. No other exoskeletons showed significant improvements.

Conclusion: In conclusion, the actively controlled exoskeleton HAL showed improvement in all outcomes of interest suggesting that neuroplasticity could be induced with HAL rehabilitation allowing the weakened bioelectrical signals to transcend the SCI to show genuine improvements.

In this review, HAL was compared with nine other passively controlled exoskeleton-type devices (devices that repeatedly perform movements through robotic control). The results clearly demonstrated that only HAL induces neuroplasticity and provides comprehensive therapeutic effects across multiple health outcomes associated with spinal cord injury (SCI).

The paper discusses that the repetitive neuromuscular process established between the central and peripheral nervous systems—made possible by HAL's core principles—facilitates the learning and reinforcement of neural signaling in the brain and spinal cord. This process ultimately leads to the reconstruction and reactivation of spinal circuits below the site of spinal cord injury and the partial reinnervation of neural pathways.

Through this mechanism of inducing neuroplasticity, HAL demonstrated consistent improvements not only in primary mobility functions such as walking ability but also in secondary health indicators, including urinary and bowel function (continence), pain reduction, and overall quality of life (QoL).

Cybernic Treatment for Spinal Cord Injury

Substantial walking improvement even in chronic SCI (avg. ~7 years post-injury)

Prospective study at BG University Hospital Bergmannsheil (Bochum, Germany)

Study design

55	chronic SCI patients
avg. 6.85 yrs	since injury
60	HAL treadmill gait training sessions (12 weeks × 5/week)
Assessed without HAL	before and after treatment

10m walking speed **~2x**

Baseline → 12 weeks. Mean 10MWT time (70.5 s → 35.2 s, –47%) converted to speed.

6-minute walk distance

~1.5x

Walking endurance also improved

Less reliance on walking aids

24 / 55 patients

43.6% of patients
WISCI II improved by 1.69 pts on avg.

Based on analysis and evaluation of prior research (note) and extensive clinical data accumulated at BG University Hospital Bergmannsheil (Bochum), HAL was accepted into the G-BA's testing scheme for public health insurance.

Source: Grasmücke D, et al. Neurosurg Focus. 2017;42(5):E15. doi:10.3171/2017.2.FOCUS171
Note: Single-arm pre/post study (no control group). Figures as reported in the paper. Percentage changes in 10MWT time and 6MWT distance are as reported; "~2x speed" is derived from mean 10MWT time.

US FDA marketing clearance obtained in 2017 based on clinical data including this study

In Germany, a trial toward public health insurance coverage has started (statutory accident insurance already covers HAL)

Trial Toward German Public Health Insurance Coverage

Trial toward German public health insurance coverage started (August 2026)
G-BA bears scientific support and evaluation costs; trial treatment costs are reimbursed by public health insurance

German public health insurance testing scheme (Erprobung, Section 137e, Social Code Book V)

A scheme under which the G-BA (Federal Joint Committee), the highest decision-making body of German public health insurance, defines a trial framework for promising new treatment methods and, after the trial is conducted and evaluated by an independent scientific institution, decides on coverage. The G-BA bears the cost of scientific support and evaluation, and treatment costs within the trial are reimbursed by public health insurance.

Trial name: EFeQT

Target condition	Chronic spinal cord injury
Study design	Multicenter randomized controlled trial (RCT)
Planned enrollment	180 patients
Treatment period	12 weeks, 5 sessions/week, up to 60 sessions
Assessment / follow-up	Walking function, etc. assessed; 6-month follow-up after treatment

HAL costs during the trial are covered by public health insurance
€334.71 (approx. ¥59,000) per session
(up to 60 sessions per patient)
***A separate fee is set for medical institutions for delivering treatment**

First patient treated in August 2026

Global Expansion of Cybernics and Strengthening of International Collaboration

Strategy to promote Cybernics as a global platform

Strengthening cooperation with politics/government/academia/related industries around the world



Cyberdyne Care Robotics
(Germany)

CYBERDYNE HQ

EMEA Base
Cyberdyne Care Robotics GmbH (Germany)



Cooperselios
(Italy)



PERKESO – REHABILITATION CENTRE MELALA
(Malaysia)

APAC Base
CYBERDYNE MALAYSIA SDN. BHD.



Singapore General Hospital
(Singapore)



RISE Healthcare Group
(USA California)



Brooks Rehabilitation
(US Florida)

Americas Base
CYBERDYNE USA INC.

EMEA : Europe, Middle East and Africa

Deployment of Cybernics Technology in Malaysia

One of Southeast Asia's largest medical complexes: the "National Neuro-Robotic and Cybernics Rehabilitation Centre"

Pusat Rehabilitasi PERKESO Sultan Nazrin Shah





- ✓Located in Ipoh, Perak, northern Malaysia
- ✓Phase 1 project
  - ✓15.6 hectares (approx. 38.5 acres)
  - ✓Total floor area: approx. 86,400 m²
- ✓Capacity for 700 patients at any time

Largest deployment at a single facility (65 units)

In addition to HAL, collaborating with other Cybernics products and C-Startup companies we invest in, to become a hub for deploying the Cybernics industry in society

PERKESO National Neuro-Robotic and Cybernics Rehabilitation Centre: aerial view and exterior (photos: PERKESO)

Deployment of Cybernics Technology in Malaysia

Official opening of the “National Neuro-Robotic and Cybernics Rehabilitation Centre” (June 2026)







PERKESO National Neuro-Robotic and Cybernics Rehabilitation Centre: opening ceremony and interior (photos: PERKESO)


Social implementation of Cybernics (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCSO/PERKESO (Malaysia Public Social Security Organization)

SOCSO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (15 facilities)



★ SOCSO/PERKESO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT

January 2024: The Minister of Human Resources requested the nationwide expansion of SOCSO (PERKESO) rehabilitation centers (three more locations, including Ipho, within five years).



https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129

Strategic Alliance with Pegasus Tech Ventures (US)

Accelerating business creation and global expansion in “HCPS Cybernics with Physical AI”



Pegasus Tech Ventures, Inc.

- Global venture capital firm based in Silicon Valley
- Operates an innovation platform connecting promising startups and leading companies worldwide

Purpose of the strategic alliance

✓ Strengthen access to promising startups, advanced technologies and innovation ecosystems worldwide

✓ Promote technology development and business co-creation in “HCPS Cybernics with Physical AI”

Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.


CYBERDYNE